Related Experiment Video
Updated: Aug 10, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
Published on: July 28, 2010
Variation of cytokine patterns related to therapeutic response in diffuse cutaneous leishmaniasis
G Bomfim1, C Nascimento, J Costa
1Serviço de Imunologia (HUPES-FAMED), Universidade Federal da Bahia, Brazil.
Insights
Diffuse cutaneous leishmaniasis patients show altered cytokine profiles, with low interferon-gamma (IFN-γ) during active disease and transient increases post-treatment. This immune response is insufficient to prevent disease relapse.
Area of Science:
- Immunology
- Parasitology
- Dermatology
Background:
- Diffuse cutaneous leishmaniasis (DCL) is a rare, disseminated form of leishmaniasis.
- DCL is characterized by cutaneous nodules and anergy to leishmanial antigens.
- Previous studies noted low IFN-γ in DCL skin lesions during active disease.
Purpose of the Study:
- To investigate cytokine mRNA expression patterns in DCL patients.
- To correlate cytokine profiles with disease stages and treatment response.
- To explore immune factors contributing to DCL pathogenesis and relapse.
Main Methods:
- Analysis of cytokine mRNA expression (IFN-γ, IL-2, IL-4, IL-10) in skin lesions and peripheral blood mononuclear cells (PBMCs).
- Comparison of cytokine patterns during active disease, post-treatment, and clinical relapse.
- Correlation of cytokine expression with clinical status.
Main Results:
- Active DCL showed no IFN-γ mRNA but expressed IL-2, IL-4, and IL-10 mRNA.
- Transient healing correlated with IFN-γ and low IL-10 mRNA expression.
- Relapse was associated with decreased IFN-γ and absent IL-10 mRNA.
Conclusions:
- Cytokine profiles in DCL vary significantly across disease stages.
- IFN-γ expression correlates with clinical improvement but does not prevent relapse.
- Other immune factors beyond Th1/Th2 balance may impair anti-Leishmania responses in DCL.
Abstract:
Diffuse cutaneous leishmaniasis is a rare entity characterized by disseminated cutaneous nodules associated with specific anergy to leishmanial antigens. A low but not absent IFN-gamma expression by cells present in cutaneous lesions has been documented during the active phase of diffuse cutaneous leishmaniasis. In this study we confirm this observation, and extend it by showing a similar pattern in peripheral blood mononuclear cells and the variation of mRNA cytokine expression pattern during different stages of the disease. During active disease, patients did not express mRNA for IFN-gamma, while expressing mRNA for IL-2, IL-4, and IL-10. In contrast, an expression of IFN-gamma and low IL-10 was observed after treatment-induced transient healing of cutaneous lesions. In three patients we have been able to analyze a third PBMC sample obtained after clinical relapse, documenting in all of them decreased IFN-gamma expression with no expression of IL-10. Although there was an association between the appearance of IFN-gamma expression and clinical improvement, with marked expression of IFN-gamma mRNA and decreased expression of mRNA for IL-10 after treatment, this was not sufficient to prevent relapse in these patients. Therefore, it is possible that factors other than the cytokines characteristic of the Th1 and Th2 balance are implicated in the inability of diffuse cutaneous leishmaniasis patients to mount an anti-Leishmania immune response causing clinical improvement.
Related Concept Videos
Leishmaniasis
Antiprotozoal Agents

